Xu, W., Zhang, H., Ye, D. (2025). Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma: 1 year updated results from UC-001, a single-center, single-arm, phase II trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.4525